Information  X 
Enter a valid email address

IXICO plc (IXI)

  Print   

Friday 29 January, 2021

IXICO plc

PDMR Dealing

RNS Number : 3669N
IXICO plc
29 January 2021
 

 

IXICO plc

("IXICO" or the "Company")

 

PDMR Dealing

Issue of Equity on exercise of options

 

 

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience , announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 156,471 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options by the VP Alliance Management (PDMR).

 

The New Shares are expected to be admitted to trading on AIM on 5 February 2021.

 

Total voting rights

 

Application has been made for admission to trading on AIM of 156,471 New Shares.  Admission of the New Shares on AIM is expected to become effective at 8.00 a.m. on 5 February 2021, following which there will be in total 47,292,939 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.

 

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.

 

T he below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

 

Details of PDMR transaction

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Sylke Grootoonk

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (VP Alliance Management)

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

IXICO plc

b)

 

LEI

 

 

2138005M1F59O6HWSA97

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

 

 

Identification code

GB00BCLY7L40

 

 

b)

 

Nature of the transaction

 

 

Exercise of options

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Exercise Price(s)

Volume(s)

 

 

 

30.5p

112,942

 

 

 

34.0p

43,529

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

1 56,471 shares

 

 

- Price

31.5p

 

 

e)

 

Date of the transaction

 

 

5 Feburary 2021

f)

 

Place of the transaction

 

 

N/A

 

 

For further information please contact:

 

IXICO plc

+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

 

 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

 

Michael F Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

+44 (0)20 7933 8780  

Paul McManus /  Lianne Cawthorne /

[email protected]

Alice Woodings

 

 

 

 

 

 

 

 

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

 

More information is available on www.IXICO.com   and follow us on Twitter @IxicOplc  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKCBDKBKDADB

a d v e r t i s e m e n t